Search Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupGastroenterologic OncologySarcomasSarcomas (ped.)DiseaseLiver Sarcoma UndifferentiatedRhabdomyosarcomaSoft Tissue SarcomaSubgroupICD10C49.-MeSHRhabdomyosarcoma, EmbryonalSequenceVAIA III, Soft Tissue SarcomaChemotherapyChemo-substanceDactinomycinDoxorubicinIfosfamideVincristineChemo-substanceDactinomycinDoxorubicinIfosfamideVincristineChemo-substanceDactinomycinDoxorubicinIfosfamideVincristineChemo-substanceDactinomycinDoxorubicinIfosfamideVincristineNo. Substances3 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimNo. Substances8Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)Febrile NeutropeniaNeutropeniaOral Mucositis only studiesPublicationAuthorTreuner J. Koscielniak EDiseaseWeichteilsarkom, HROriginCWS 2002 Protokoll der Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH)Protocols in Revision 4 protocols foundProtocols under revision.VAIA III Block 1 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID657 V1.2)VAIA III Block 2 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID659 V1.3)VAIA III Block 3,4,6 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID660 V1.2)VAIA III Block 5,7,8,9 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID661 V1.3)
